{"disease":{"id":"acute-myeloid-leukemia-in-relapsed-or-refractory","name":"acute myeloid leukemia in relapsed or refractory"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03755154","title":"Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":60,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false},{"nct_id":"NCT04541277","title":"Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":55,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT06906380","title":"A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":49,"lead_sponsor_name":"ARCE Therapeutics, Inc.","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}